Evidence map›Paper›PMID 35938167›Full record

ReviewFrontiers in cell and developmental biology2022

Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate

Hengfeng Zhou, Qiangrong He, Chao Li, Bassam Lutf Mohammed Alsharafi, Liang Deng, Zhi Long, Yu Gan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Neuroendocrine prostate cancer (NEPC)-associatedCancer pathogenesis and therapy · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hengfeng ZhouAndrology Center, Department of Urology, the Third Xiangya Hospital, Central South University, Changsha, China.
Qiangrong HeAndrology Center, Department of Urology, the Third Xiangya Hospital, Central South University, Changsha, China.
Chao LiAndrology Center, Department of Urology, the Third Xiangya Hospital, Central South University, Changsha, China.
Bassam Lutf Mohammed AlsharafiAndrology Center, Department of Urology, the Third Xiangya Hospital, Central South University, Changsha, China.
Liang DengAndrology Center, Department of Urology, the Third Xiangya Hospital, Central South University, Changsha, China.
Zhi LongAndrology Center, Department of Urology, the Third Xiangya Hospital, Central South University, Changsha, China.
Yu GanDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNThird Xiangya Hospital · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment (TME) is a microecology consisting of tumor and mesenchymal cells and extracellular matrices. The TME plays important regulatory roles in tumor proliferation, invasion, metastasis, and differentiation. Neuroendocrine differentiation (NED) is a mechanism by which castration resistance develops in advanced prostate cancer (PCa). NED is induced after androgen deprivation therapy and neuroendocrine prostate cancer (NEPC) is established finally. NEPC has poor prognosis and short overall survival and is a major cause of death in patients with PCa. Both the cellular and non-cellular components of the TME regulate and induce NEPC formation through various pathways. Insights into the roles of the TME in NEPC evolution, growth, and progression have increased over the past few years. These novel insights will help refine the NEPC formation model and lay the foundation for the discovery of new NEPC therapies targeting the TME.

Indexed as

androgen deprivation therapy (ADT)castration-resistant prostate cancerlineage plasticityneuroendocrine prostate cancer (NEPC)tumor microenvironment

Identifiers

PMID35938167
PMCPMC9355504
OpenAlexW4286586737

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.